Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Recruiting × NSCLC × cemiplimab × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 18 Neoplasm Metastasis 6 Neoplasms 5 Melanoma 5 Lung Neoplasms 5 Carcinoma, Renal Cell 5 Squamous Cell Carcinoma of Head and Neck 4 Skin Neoplasms 4 Ovarian Neoplasms 4 Triple Negative Breast Neoplasms 3 Fallopian Tube Neoplasms 3 Breast Neoplasms 3 Adenocarcinoma 3 Uveal Melanoma 2 Urinary Bladder Neoplasms 2 Recurrence 2 Prostatic Neoplasms 2 Pancreatic Neoplasms 2 Mycosis Fungoides 2 Multiple Myeloma 2 Lymphoma, T-Cell 2 Lymphoma, Large-Cell, Anaplastic 2 Head and Neck Neoplasms 2 Endometrial Neoplasms 2 Colonic Neoplasms 2 Carcinoma, Squamous Cell 2 Carcinoma, Large Cell 2 Adrenocortical Carcinoma 2 Vaccinia 1 Uterine Cervical Neoplasms 1

Interventions

Drug Therapy 4 Radiotherapy 3 osimertinib 2 aflutinib 2 Radiosurgery 2 Pemetrexed 2 Carboplatin 2 trilaciclib 1 toripalimab 1 tislelizumab 1 sugemalimab 1 spartalizumab 1 sintilimab 1 pembrolizumab 1 cemiplimab 1 Vinorelbine 1 Platinum 1 Paclitaxel 1 Immune Checkpoint Inhibitors 1 Gemcitabine 1 Docetaxel 1 Cisplatin 1 Chemotherapy, Adjuvant 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06865339 2025-09-10

TRIPL

Albert Einstein College of Medicine

Phase 2 Recruiting

NSCLC

Data powered by HemOnc (CC BY 4.0) Colophon ⚡